• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Verrica Pharmaceuticals Inc.

    4/22/25 7:18:16 AM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VRCA alert in real time by email
    DEFA14A 1 d900106ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

     

     

    Filed by the Registrant ☒        Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under § 240.14a-12

    Verrica Pharmaceuticals Inc.

    (Name of Registrant as Specified In Its Charter)

     

    (Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

    Payment of Filing Fee (Check all boxes that apply)

     

    ☒

    No fee required

     

    ☐

    Fee paid previously with preliminary materials

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     
     


    LOGO

    VERRICA PHARMACEUTICALS INC. 44 W. GAY STREET, SUITE 400 WEST CHESTER, PA 19380 Your Vote Counts! VERRICA PHARMACEUTICALS INC. 2025 Annual Meeting Vote by June 4, 2025 11:59 PM ET V71989-P31235 You invested in VERRICA PHARMACEUTICALS INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 5, 2025. Get informed before you vote View the Notice and Proxy Statement and Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 22, 2025. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Point your camera here and vote without entering a control number Vote in Person at the Meeting* June 5, 2025 10:00 AM EDT Company’s Headquarters 44 W. Gay St., Suite 400 West Chester, PA 19380 *Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares.


    LOGO

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Voting Items Board Recommends 1. Election of Directors Nominees: 01) Gavin Corcoran 02) Diem Nguyen 03) Sean Stalfort For 2. Approval, on an advisory basis, of the compensation of the Company’s named executive officers as disclosed in the proxy statement. For 3. Ratification of the selection by the Audit Committee of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. For 4. Approval of a series of alternate amendments to the Company’s Amended and Restated Certificate of Incorporation to effect, at the option of the Board of Directors, a reverse stock split of the Company’s common stock at a reverse stock split ratio ranging from 1-for-10 to 1-for-30, inclusive, with the effectiveness of one of such amendments and the abandonment of the other amendments, or the abandonment of all amendments, to be determined by the Board of Directors, in its sole discretion, prior to the date of the 2026 Annual Meeting of Stockholders. For NOTE: Such other business as may properly come before the meeting, including any adjournment or postponement thereof. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V71990-P31235

    Get the next $VRCA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VRCA

    DatePrice TargetRatingAnalyst
    11/6/2024Buy → Neutral
    H.C. Wainwright
    11/5/2024Outperform → Sector Perform
    RBC Capital Mkts
    7/25/2023$10.00Hold → Buy
    Needham
    3/22/2023$10.00Buy
    Jefferies
    2/13/2023$4.00 → $11.00Sector Perform → Outperform
    RBC Capital Mkts
    5/25/2022$16.00 → $4.00Outperform → Sector Perform
    RBC Capital Mkts
    3/10/2022$20.00Buy
    Brookline Capital
    3/3/2022$20.00 → $18.00Buy
    Needham
    More analyst ratings

    $VRCA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Corcoran Gavin

      4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

      4/2/25 4:32:51 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Corcoran Gavin claimed ownership of 20 shares (SEC Form 3)

      3 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

      4/2/25 4:31:50 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CMO Rosenberg Noah L.

      4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

      3/26/25 7:10:45 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRCA
    Financials

    Live finance-specific insights

    See more
    • Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025

      WEST CHESTER, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, May 13, 2025, to discuss the Company's financial results for the first quarter ending March 31, 2025, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-800-343-4136 (domestic) or 1-203-518-9843 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minutes before the start of

      5/7/25 8:00:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025

      WEST CHESTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, March 11, 2025, to discuss the Company's financial results for the fourth quarter and full year ending December 31, 2024, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-800-445-7795 (domestic) or 1-785-424-1699 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minut

      3/3/25 7:00:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results

      - Reports YCANTH® revenue, net of $4.9M for second quarter of 2024 along with the expansion of YCANTH's distribution footprint to include Cencora, Inc. as a specialty distributor – - Announces positive preliminary topline results of Phase 2 clinical study of VP-315 for the treatment of patients with basal cell carcinoma – - Continues to progress preparation for global Phase 3 Common Warts trial with initiation expected in 1H 2025 – - Conference Call Scheduled for Today at 8:30 am ET – WEST CHESTER, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical i

      8/14/24 7:45:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRCA
    Leadership Updates

    Live Leadership Updates

    See more
    • Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition

      – Company reported $0 in product shipments in the third quarter of 2024 and recognized negative net product revenue of $1.9 million, including a provision for product returns of $1.7 million– – Company expects existing distributor inventory to support most demand for dispensed applicator units into the first quarter of 2025 – – Company continues to look for ways to manage expenses and expand access to YCANTH® for the treatment of molluscum contagiosum – – Company announces new senior leadership with appointments of Dr. Jayson Rieger as Chief Executive Officer and John Kirby as Interim Chi

      11/4/24 4:05:00 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals Reports Second Quarter 2021 Financial Results

      WEST CHESTER, Pa., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the second quarter ended June 30, 2021. "This quarter, we continued to ramp up commercial preparations for the potential FDA approval of VP-102, our lead product candidate for the treatment of molluscum contagiosum, including strengthening our senior leadership team and ensuring patient access to VP-102 through productive dialogue with medical providers and payors," said Ted White, Verrica's President and Chief Executive Officer. "With a

      8/10/21 7:30:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals Announces Appointment of Terry Kohler as Chief Financial Officer

      Company strengthens management team in anticipation of the potential commercial launch of VP-102, if approved WEST CHESTER, Pa., July 09, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Terry Kohler as Chief Financial Officer. Mr. Kohler is a strategic and operational finance leader with over 20 years of commercial business experience, most recently at a global pharmaceutical company with annual revenues over $2 billion. Mr. Kohler is replacing Brian Davis, who is leaving Verrica to pursue other opportunities. "Te

      7/9/21 7:30:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRCA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Stalfort John A Iii bought 1,123,595 shares and received a gift of 50,000 shares, increasing direct ownership by 168% to 1,873,800 units (SEC Form 4)

      4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

      11/26/24 4:15:08 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and President Rieger Jayson bought 280,898 shares and received a gift of 50,000 shares, increasing direct ownership by 60% to 882,826 units (SEC Form 4)

      4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

      11/26/24 4:15:13 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Manning Paul B bought 22,921,348 shares and gifted 450,000 shares (SEC Form 4)

      4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

      11/26/24 4:15:07 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRCA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $VRCA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $VRCA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more

    $VRCA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Verrica Pharmaceuticals downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Verrica Pharmaceuticals from Buy to Neutral

      11/6/24 6:25:52 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals downgraded by RBC Capital Mkts

      RBC Capital Mkts downgraded Verrica Pharmaceuticals from Outperform to Sector Perform

      11/5/24 6:29:20 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals upgraded by Needham with a new price target

      Needham upgraded Verrica Pharmaceuticals from Hold to Buy and set a new price target of $10.00

      7/25/23 7:35:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Verrica Pharmaceuticals Inc.

      SC 13G/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)

      12/9/24 6:22:49 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Verrica Pharmaceuticals Inc.

      SC 13D/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)

      11/26/24 4:15:26 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Verrica Pharmaceuticals Inc.

      SC 13G/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)

      11/14/24 9:32:46 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for YCANTH issued to VERRICA PHARMACEUTICALS INC

      Submission status for VERRICA PHARMACEUTICALS INC's drug YCANTH (ORIG-1) with active ingredient CANTHARIDIN has changed to 'Approval' on 07/21/2023. Application Category: NDA, Application Number: 212905, Application Classification: Type 5 - New Formulation or New Manufacturer

      7/21/23 4:54:32 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025

      WEST CHESTER, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, May 13, 2025, to discuss the Company's financial results for the first quarter ending March 31, 2025, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-800-343-4136 (domestic) or 1-203-518-9843 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minutes before the start of

      5/7/25 8:00:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York

      WEST CHESTER, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Citizens Life Sciences Conference in New York City. Citizens Life Sciences Conference, May 7-8, 2025Event details:Date: Wednesday, May 7, 2025Time: 3:00 pm ETLocation: New York Hilton Midtown, New York Participants may access a live webcast of the event by clicking the link here. The webcast can also be accessed in the Invest

      4/30/25 8:00:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025

      – Company generated quarterly sequential growth with Q1 YCANTH® dispensed applicator units rising above 10,000 for the first time in a quarter – – As YCANTH distributor inventory levels have normalized, Company expects that dispensed applicator units will now more closely track demand and gross revenue – WEST CHESTER, Pa., April 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Company experienced strong demand-led growth for YCANTH® in the first quarter of 2025, with the number of dispensed applicato

      4/7/25 8:00:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRCA
    SEC Filings

    See more
    • SEC Form DEFR14A filed by Verrica Pharmaceuticals Inc.

      DEFR14A - Verrica Pharmaceuticals Inc. (0001660334) (Filer)

      4/30/25 6:06:32 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Verrica Pharmaceuticals Inc.

      8-K - Verrica Pharmaceuticals Inc. (0001660334) (Filer)

      4/25/25 4:21:12 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Verrica Pharmaceuticals Inc.

      DEFA14A - Verrica Pharmaceuticals Inc. (0001660334) (Filer)

      4/22/25 7:18:16 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care